Persistent or Transient Human β Cell Dysfunction Induced by Metabolic Stress: Specific Signatures and Shared Gene Expression with Type 2 Diabetes

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Lorella Marselli - , University of Pisa (Author)
  • Anthony Piron - , Université libre de Bruxelles (ULB) (Author)
  • Mara Suleiman - , University of Pisa (Author)
  • Maikel L. Colli - , Université libre de Bruxelles (ULB) (Author)
  • Xiaoyan Yi - , Université libre de Bruxelles (ULB) (Author)
  • Amna Khamis - , Université de Lille (Author)
  • Gaelle R. Carrat - , Imperial College London (Author)
  • Guy A. Rutter - , Imperial College London, Nanyang Technological University (Author)
  • Marco Bugliani - , University of Pisa (Author)
  • Laura Giusti - , University of Pisa, University of Camerino (Author)
  • Maurizio Ronci - , University "G. d'Annunzio" of Chieti-Pescara (Author)
  • Mark Ibberson - , Swiss Institute of Bioinformatics (Author)
  • Jean Valery Turatsinze - , Université libre de Bruxelles (ULB) (Author)
  • Ugo Boggi - , University of Pisa, Cisanello Hospital (Author)
  • Paolo De Simone - , University of Pisa, Cisanello Hospital (Author)
  • Vincenzo De Tata - , University of Pisa (Author)
  • Miguel Lopes - , Université libre de Bruxelles (ULB) (Author)
  • Daniela Nasteska - , Université libre de Bruxelles (ULB) (Author)
  • Carmela De Luca - , University of Pisa (Author)
  • Marta Tesi - , University of Pisa (Author)
  • Emanuele Bosi - , University of Pisa (Author)
  • Pratibha Singh - , Université libre de Bruxelles (ULB) (Author)
  • Daniela Campani - , University of Pisa (Author)
  • Anke M. Schulte - , Sanofi-Aventis (Author)
  • Michele Solimena - , Molecular Diabetology, TUD Dresden University of Technology, German Center for Diabetes Research (DZD e.V.) (Author)
  • Peter Hecht - , Sanofi-Aventis (Author)
  • Brian Rady - , Janssen Pharmaceutica NV (Author)
  • Ivona Bakaj - , Janssen Pharmaceutica NV (Author)
  • Alessandro Pocai - , Janssen Pharmaceutica NV (Author)
  • Lisa Norquay - , Janssen Pharmaceutica NV (Author)
  • Bernard Thorens - , University of Lausanne (Author)
  • Mickaël Canouil - , Université de Lille (Author)
  • Philippe Froguel - , Imperial College London (Author)
  • Decio L. Eizirik - , Université libre de Bruxelles (ULB), Indiana Biosciences Research Institute (IBRI) (Author)
  • Miriam Cnop - , Université libre de Bruxelles (ULB) (Author)
  • Piero Marchetti - , University of Pisa (Author)

Abstract

Pancreatic β cell failure is key to type 2 diabetes (T2D) onset and progression. Here, we assess whether human β cell dysfunction induced by metabolic stress is reversible, evaluate the molecular pathways underlying persistent or transient damage, and explore the relationships with T2D islet traits. Twenty-six islet preparations are exposed to several lipotoxic/glucotoxic conditions, some of which impair insulin release, depending on stressor type, concentration, and combination. The reversal of dysfunction occurs after washout for some, although not all, of the lipoglucotoxic insults. Islet transcriptomes assessed by RNA sequencing and expression quantitative trait loci (eQTL) analysis identify specific pathways underlying β cell failure and recovery. Comparison of a large number of human T2D islet transcriptomes with those of persistent or reversible β cell lipoglucotoxicity show shared gene expression signatures. The identification of mechanisms associated with human β cell dysfunction and recovery and their overlap with T2D islet traits provide insights into T2D pathogenesis, fostering the development of improved β cell-targeted therapeutic strategies.

Details

Original languageEnglish
Article number108466
JournalCell reports
Volume33
Issue number9
Publication statusPublished - 1 Dec 2020
Peer-reviewedYes

External IDs

PubMed 33264613

Keywords

Sustainable Development Goals

Keywords

  • beta cells, damage, endoplasmic reticulum stress, eQTL, glucolipotoxicity, human pancreatic islets, lipoglucotoxicity, recovery, transcriptome, type 2 diabetes